stockrowFoghorn Therapeutics Inc.
FHTX Healthcare Biotechnology
Foghorn Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $30.9 million, up 36.8% from fiscal 2024.
- Revenue
- +112.7%
- EPS
- +64.3%
- Free cash flow
- +14.9%
Quarter to June 2026, against a year earlier
Follow FHTX
Alert me
Foghorn Therapeutics Inc. (FHTX) EV/Sales
As of 6 November 2026, Foghorn Therapeutics Inc. (FHTX) trades at a EV/Sales of −0.4×. Over the past ten years it has ranged from −10.9× (May 2022) to 842× (December 2021); the current reading is higher than 14% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 6.5× | 314.13% |
| FY2024 | 1.6× | (5.76%) |
| FY2023 | 1.7× | — |
| FY2022 | −2.9× | — |
| FY2021 | 543× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 5.4× | (9.61%) |
| Mar 2026 | 5.9× | (8.26%) |
| Dec 2025 | 6.5× | 8.15% |
| Sep 2025 | 6.0× | 24.60% |
| 20 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| FHTX Foghorn Therapeutics Inc. | −0.4× |
| NKTX Nkarta, Inc. compare | n/m |
| PYPD PolyPid Ltd. compare | n/m |
| NERV Minerva Neurosciences, Inc compare | n/m |
| ENGN enGene Therapeutics Inc compare | n/m |
| CDXS Codexis, Inc. compare | 1.0× |
| CHRS Coherus Oncology, Inc. compare | 4.4× |
| HUMA Humacyte, Inc. compare | 41.4× |
| ARMP Armata Pharmaceuticals, Inc. compare | 69.2× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)